金尔伦治疗急性重型脑外伤的临床研究  

Clinical study of naloxone in treatment of traumatic brain injury

作　　者：陈亿民[1] 林庭凯[1] 洪湖强 林宜生[1] 

机构地区：[1]广东汕头市第二人民医院神经外科,汕头515011

出　　处：《实用神经疾病杂志》2005年第2期1-2,共2页

摘　　要：目的　探讨金尔伦治疗急性重型颅脑损伤患者的疗效和安全性。方法　 13 1名急性重型颅脑伤病人随机分成金尔伦治疗组 (n =62 )和对照组 (n =69) ,观察治疗早期病人GCS评分变化和远期疗效。结果　金尔伦组患者GCS评分在用药后第 5d开始明显优于对照组 (P <0 0 5 ) ;金尔伦组病死率 2 4 2 % ,对照组病死率 5 0 7% ,两组相比有显著性差异 (P <0 0 1)。结论　金尔伦可以降低急性重型颅脑外伤病人颅内压的升高幅度 ,缩短昏迷时间 ,降低伤残率 ,促进病人神经功能恢复 ,改善预后。Objective To assess the efficacy and safety of naloxone in treatment traumatic brain injury.Methods All 131 patients with traumatic brain injury were divided into two groups randomized (62 cases were treated with NLX and 69 cases were control) . The clinical data, Glasgow outcome scale and the efficacy of naloxone were analysed.Results Glasgow outcome scale in naloxone group was significantly better than that in control group starting at 5th day after treatment (P<0.05). The mortality of naloxone group was 24.2%, the mortality of control group was 50.7 %. There was significant difference between two groups(P<0.01)).Conclusion A successive early large dosage of NLX can relieve traumatic brain injury and improve the recovery of coma and reduce the disability in traumatic brain injury.

关 键 词：金尔伦 治疗 病人 对照组 GCS评分 急性重型脑外伤 病死率 患者 临床研究 伤残率 

分 类 号：R651.15[医药卫生—外科学] R743.305[医药卫生—临床医学]